Table 2.
Individual patient-level data meta-analysis: Patient characteristics, total (unmatched) cohort and IPTW (matched) cohort
| Variables at baseline | Total CHB cohort |
IPTW cohort* |
||||
|---|---|---|---|---|---|---|
| Non-fatty liver (n=8,625) | Fatty liver (n=4,637) | P-value | Non-fatty liver (n=6,955) | Fatty liver (n=3,346) | P-value | |
| Age | 46.6±11.5 | 48.6±11.4 | <0.0001 | 47.4±11.5 | 47.6±11.2 | 0.42 |
| Male gender | 5,559 (64.7) | 3,539 (77.1) | <0.0001 | 2,358 (65.3) | 2,364 (66.2) | 0.40 |
| Baseline diabetes mellitus | 599 (7.4) | 659 (15.2) | 0.002 | 387 (10.7) | 385 (10.8) | 0.93 |
| Baseline cirrhosis | 527 (6.1) | 173 (3.7) | <0.0001 | 193 (5.3) | 187 (5.2) | 0.84 |
| ALT | 80±246 | 78±230 | <0.0001 | 65±189 | 67±189 | 0.63 |
| Positive HBeAg | 1,634 (21.4) | 721 (19.3) | 0.01 | 693 (19.2) | 680 (19.1) | 0.88 |
| Log HBV DNA | 3.9±2.6 | 3.9±2.6 | 0.60 | 3.8±2.6 | 3.8±2.6 | 0.88 |
| Received antiviral treatment | 2,479 (28.7) | 1,479 (31.9) | <0.0001 | 1,083 (30.0) | 1,083 (30.3) | 0.72 |
Data presented as mean±standard deviation or number (%) for total CHB cohort and as weighted count (%) for IPTW cohort unless otherwise specified.
CHB, chronic hepatitis B; NAFLD, non-alcoholic fatty liver disease; DM, diabetes mellitus; ALT, alanine transaminases; IPTW: Inverse Probability Treatment Weighting; HBV, hepatitis B virus.
*
Inverse Probability Treatment Weighting, matched for age, sex, baseline cirrhosis, diabetes mellitus, ALT, HBeAg, log HBV DNA, and antiviral treatment status.